have loss for the period of Baht 230.0 million as compared to the 2018 , the company and its subsidiaries have loss for the period of Baht 174.4 million, increased Baht 55.6 million or 32% for the
. 022 / 2018 August 9, 2018 Subject Explanation of the operating performance for 3-month period ended June 30, 2018 To Managing Director The Stock Exchange of Thailand Pan Asia Footwear Public Company
/2561 November 12, 2018 Subject: Management’s discussion and analysis of the Company’s operating results for Q3/2018 period To: President The Stock Exchange of Thailand DOD Biotech Public Company Limited
Page 1 Date 13 May 2020 Re: Management Discussion & Analysis for the 3-months period Ended 31 March 2020 To The President of the Stock Exchange of Thailand (SET) CHAOPRAYAMAHANAKORN PUBLIC COMPANY
period of Baht 34.9 million as compared to the 2019 , the company and its subsidiaries have loss for the period of Baht 339.9 million, decreased Baht 305.0 million or 90% for the following main reasons; 1
www.interpharma.co.th IP_OCS/010/2562 November 10, 2019 Subject Management’s discussion and analysis for the third quarter of 2019 To President The Stock Exchange of Thailand Interpharma Public Company Limited (“the
-ร่าง- UNOFFICIAL TRANSLATION Codified up to No. 3 As of 22 December 2016 Readers should be aware that only the original Thai text has legal force and that this English translation is strictly for
- ร่าง - 1 Aug 10, 2017 Subject Management Discussion and Analysis for the period of three months ended 30th June 2017 To President of the Stock Exchange of Thailand Secretary of the Office of
three-month period ended March31, 2020. The Group's sales and net profit totaled Bt3,259.7 million and Bt424.8 million, respectively, compared to Bt3,113.9 million and Bt268.6 million in the first quarter
structural change in the business outlook of PET, and is an oppor- tunity for well-managed and committed PET producers like IVL to align supply reliability to customers. We benefitted from the instability